J Anesth:右美托咪定与咪达唑仑单次很低剂量用于预防儿童苏醒期谵妄的比较:随机对照研究

2019-11-30 anesthGH 罂粟花

小儿在七氟醚麻醉后常出现苏醒期谵妄(ED),为保证患儿安全,应予以预防。本研究采用前瞻性、双盲、随机、对照研究旨在比较最低有效剂量的咪达唑仑与右美托咪定预防儿童扁桃体切除术后ED的疗效。

背景与目的

小儿在七氟醚麻醉后常出现苏醒期谵妄(ED),为保证患儿安全,应予以预防。本研究采用前瞻性、双盲、随机、对照研究旨在比较最低有效剂量的咪达唑仑与右美托咪定预防儿童扁桃体切除术后ED的疗效。

方  法

本研究共纳入70名24个月至12岁的儿童,在扁桃体手术结束前5分钟给予咪达唑仑(0.03 mg/kg)或右美托咪定(0.3μg/kg)。ED的发生率和严重程度分别采用4分评分法和儿童苏醒期躁动(PAED)评分法评估EA发生情况。并记录苏醒期时间和术后疼痛评分。

结 果

咪达唑仑组和右美托咪定组ED发生率分别为31.3% 和26.5% (P=0.668),两组瞻望的严重程度相似(咪达唑仑组为9.6±5.8, vs.右美托咪定组为8.1±5.9 , P=0.299),两组苏醒期时间相当[咪达唑仑组11.0 (8.3–13.8) min vs. 右美托咪定组12.0 (10.0–13.5) min (P=0.218)].咪达唑仑术后疼痛评分 [0 (0–1)] 较右美托咪定组高 [0 (0–1)] (P=0.011)。

结 论

单次最小剂量的右美托咪定和咪达唑仑在预防儿童ED方面具有同等的疗效,但在手术结束时使用,不会延迟苏醒期时间。关于术后镇痛效果,尽管右美托咪定的镇痛效果明显高于咪达唑仑,但还需要进一步的临床研究来验证我们的发现。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707720, encodeId=8b671e0772063, content=<a href='/topic/show?id=9c968e01017' target=_blank style='color:#2F92EE;'>#苏醒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87010, encryptionId=9c968e01017, topicName=苏醒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ea931488603, createdName=ms1065684921169360, createdTime=Sun Oct 18 14:55:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038277, encodeId=22b220382e7dc, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Sat Feb 01 18:55:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720574, encodeId=fdd41e20574fb, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Tue Jul 21 12:55:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051479, encodeId=214f20514e965, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 22 08:55:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775486, encodeId=492f1e754867f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 04 01:55:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480563, encodeId=e8911480563b2, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Dec 02 10:55:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038899, encodeId=bd981038899c7, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Nov 30 22:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1707720, encodeId=8b671e0772063, content=<a href='/topic/show?id=9c968e01017' target=_blank style='color:#2F92EE;'>#苏醒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87010, encryptionId=9c968e01017, topicName=苏醒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ea931488603, createdName=ms1065684921169360, createdTime=Sun Oct 18 14:55:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038277, encodeId=22b220382e7dc, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Sat Feb 01 18:55:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720574, encodeId=fdd41e20574fb, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Tue Jul 21 12:55:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051479, encodeId=214f20514e965, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 22 08:55:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775486, encodeId=492f1e754867f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 04 01:55:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480563, encodeId=e8911480563b2, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Dec 02 10:55:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038899, encodeId=bd981038899c7, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Nov 30 22:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1707720, encodeId=8b671e0772063, content=<a href='/topic/show?id=9c968e01017' target=_blank style='color:#2F92EE;'>#苏醒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87010, encryptionId=9c968e01017, topicName=苏醒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ea931488603, createdName=ms1065684921169360, createdTime=Sun Oct 18 14:55:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038277, encodeId=22b220382e7dc, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Sat Feb 01 18:55:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720574, encodeId=fdd41e20574fb, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Tue Jul 21 12:55:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051479, encodeId=214f20514e965, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 22 08:55:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775486, encodeId=492f1e754867f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 04 01:55:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480563, encodeId=e8911480563b2, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Dec 02 10:55:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038899, encodeId=bd981038899c7, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Nov 30 22:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1707720, encodeId=8b671e0772063, content=<a href='/topic/show?id=9c968e01017' target=_blank style='color:#2F92EE;'>#苏醒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87010, encryptionId=9c968e01017, topicName=苏醒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ea931488603, createdName=ms1065684921169360, createdTime=Sun Oct 18 14:55:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038277, encodeId=22b220382e7dc, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Sat Feb 01 18:55:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720574, encodeId=fdd41e20574fb, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Tue Jul 21 12:55:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051479, encodeId=214f20514e965, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 22 08:55:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775486, encodeId=492f1e754867f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 04 01:55:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480563, encodeId=e8911480563b2, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Dec 02 10:55:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038899, encodeId=bd981038899c7, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Nov 30 22:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1707720, encodeId=8b671e0772063, content=<a href='/topic/show?id=9c968e01017' target=_blank style='color:#2F92EE;'>#苏醒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87010, encryptionId=9c968e01017, topicName=苏醒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ea931488603, createdName=ms1065684921169360, createdTime=Sun Oct 18 14:55:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038277, encodeId=22b220382e7dc, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Sat Feb 01 18:55:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720574, encodeId=fdd41e20574fb, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Tue Jul 21 12:55:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051479, encodeId=214f20514e965, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 22 08:55:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775486, encodeId=492f1e754867f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 04 01:55:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480563, encodeId=e8911480563b2, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Dec 02 10:55:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038899, encodeId=bd981038899c7, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Nov 30 22:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2020-03-04 amyloid
  6. [GetPortalCommentsPageByObjectIdResponse(id=1707720, encodeId=8b671e0772063, content=<a href='/topic/show?id=9c968e01017' target=_blank style='color:#2F92EE;'>#苏醒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87010, encryptionId=9c968e01017, topicName=苏醒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ea931488603, createdName=ms1065684921169360, createdTime=Sun Oct 18 14:55:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038277, encodeId=22b220382e7dc, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Sat Feb 01 18:55:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720574, encodeId=fdd41e20574fb, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Tue Jul 21 12:55:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051479, encodeId=214f20514e965, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 22 08:55:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775486, encodeId=492f1e754867f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 04 01:55:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480563, encodeId=e8911480563b2, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Dec 02 10:55:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038899, encodeId=bd981038899c7, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Nov 30 22:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1707720, encodeId=8b671e0772063, content=<a href='/topic/show?id=9c968e01017' target=_blank style='color:#2F92EE;'>#苏醒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87010, encryptionId=9c968e01017, topicName=苏醒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ea931488603, createdName=ms1065684921169360, createdTime=Sun Oct 18 14:55:00 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038277, encodeId=22b220382e7dc, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Sat Feb 01 18:55:00 CST 2020, time=2020-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720574, encodeId=fdd41e20574fb, content=<a href='/topic/show?id=2b3939e938a' target=_blank style='color:#2F92EE;'>#咪达唑仑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39793, encryptionId=2b3939e938a, topicName=咪达唑仑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f92f32859800, createdName=zhanfl, createdTime=Tue Jul 21 12:55:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051479, encodeId=214f20514e965, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 22 08:55:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775486, encodeId=492f1e754867f, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Wed Mar 04 01:55:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480563, encodeId=e8911480563b2, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Mon Dec 02 10:55:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038899, encodeId=bd981038899c7, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Nov 30 22:55:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2019-11-30 肿瘤克星

    高质量研究,读起来真爽,谢谢梅斯

    0

相关资讯

BMC Anesthesiol:右美托咪定联合舒芬太尼与舒芬太尼单独使用用于术后静脉病人自控镇痛的比较:一项系统性回顾和随机对照试验的meta分析

以往的研究表明,右美托咪定能提高术后镇痛的质量。在本研究中,我们对随机对照试验进行了Meta分析,以量化右美托咪定作为舒芬太尼佐剂用于术后病人自控镇痛(PCA)的效果。

BJA:右美托咪定镇静状态下,儿童认知记忆评估的可行性

右美托咪定对儿童记忆的影响尚未有前瞻性的研究,本研究主要确定是否能在儿童患者中获取质量可靠的数据用以建立记忆和镇静反应间的模型。采用标准的视觉图片命名任务来评估当镇静程度逐渐加深时的记忆。研究的次要观察指标建立时间与右美托咪定镇静效应(丧失语言反应)和存在认知记忆的回归模型。

烧伤后颏颈胸瘢痕挛缩患者右美托咪定镇静纤支镜引导下经鼻气管插管的体会

颏、颈、胸重度烧伤患者,临床表现为颈部瘢痕挛缩严重,下颌与前胸瘢痕粘连,患者张口困难,后仰受限。此类患者存在面罩通气困难,声门显露困难,气道表麻困难等问题,严重影响手术,威胁患者健康,实施气管内插管对麻醉医生是严峻的挑战。山东大学附属省立医院麻醉科近期采用自制的OLYMPUSLF-DP型号纤支镜气道内表麻设备先实施气管内表麻,然后再使用右美托咪定镇静,纤支镜引导下成功完成经鼻气管插管,插管过程患者

BMC Anesthesiol:右美托咪定通过激活PI3K/AKT/MTOR途径抑制七氟醚麻醉诱导的神经炎症反应

七氟醚是一种吸入性全身麻醉剂,已经成为外科中应用最广泛的吸入性麻醉剂之一。然而,先前的研究已经发现七氟醚麻醉能引起炎症反应,导致二次伤害。右美托咪定(DEX)是一种高选择性α肾上腺素受体激动剂,作为一种麻醉辅助药广泛应用于临床。在这项研究中,我们研究了DEX是否能够抑制七氟醚引起的神经炎症反应。

门诊儿科患者通过鼻腔给予右美托咪定的药代动力学及镇静作用研究

我们的目的是研究通过鼻腔内给予右美托咪定作为小儿磁共振检查镇静剂的药代动力学和镇静作用。

BMCAnest hesiology:罗哌卡因联合右美托咪定用于臂丛神经阻滞的镇痛效果

罗哌卡因联合右美托咪定与罗哌卡因单独应用于臂丛神经阻滞镇痛效果的比较,为上肢外伤手术提供更好的麻醉方式。